Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
BeOne Medicines
Amgen
AstraZeneca
CytoDyn, Inc.
Mayo Clinic
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Takeda
Bristol-Myers Squibb
Masonic Cancer Center, University of Minnesota
Repare Therapeutics
Massachusetts General Hospital
Gilead Sciences
PharmaMar
Bristol-Myers Squibb
St. Jude Children's Research Hospital
PharmaMar
BeiGene
BeiGene
Incyte Corporation
Eli Lilly and Company
Incyte Corporation
Amgen
Merck Sharp & Dohme LLC
Columbia University
UCB Pharma
M.D. Anderson Cancer Center
University of Pennsylvania
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
BeiGene
EMD Serono
CicloMed LLC
Ipsen
Agalimmune Ltd.
Alliance for Clinical Trials in Oncology
BerGenBio ASA
NanoCarrier Co., Ltd.
ImmunoGen, Inc.
Eisai Inc.
Amgen
Bristol-Myers Squibb
ImmuneSensor Therapeutics Inc.
Canadian Cancer Trials Group
Pfizer
Merck KGaA, Darmstadt, Germany
Taiho Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
BeiGene